Posted by Michael Wonder on 08 Jun 2022
Vertex announces inaxaplin (VX-147) granted breakthrough therapy designation by U.S. FDA and PRIME designation by the EMA
8 June 2022 - Vertex granted nine breakthrough therapy designations and three PRIME designations across its pipeline programs to date.
Vertex Pharmaceuticals today announced the U.S. FDA has granted inaxaplin (VX-147) breakthrough therapy designation for APOL1 mediated focal segmental glomerulosclerosis and the EMA has granted inaxaplin PRIME designation for APOL1 mediated chronic kidney disease.
